COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

April 2, 2018
CPTAC Develops Fit-for-Purpose Multiplex Immuno-MRM Assay for Profiling the DNA Damage Response Pathway

Ionizing radiation (IR) is a commonly employed cancer treatment that kills cancer cells by damaging their DNA. While the DNA damage response (DDR) pathway may be key to determining tumor responses, radiochemical...
March 21, 2018
ICPC Pilots International Student Training, Paving a Path for Tomorrow’s Cancer Researchers

The Office of Cancer Clinical Proteomics Research at the National Cancer Institute, part of the United States National Institutes of Health, is spearheading the preparationand training of the proteogenomic research workforce on an international scale.
March 12, 2018
CPTAC Identifies Novel Resistant Mechanism to PI3K Inhibitor in Triple Negative Breast Cancers

Breast cancer is the second most common cancer in women living in the United States, with triple-negative breast cancer (TNBC) accounting for approximately 15% of diagnoses. While chemotherapy is the standard-of-care in TNBC, resistance is common and...
March 5, 2018
CPTAC Releases Cancer Proteome Confirmatory Ovarian Study Data

A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying diagnostics and therapies that will improve patients’ lives. Because a comprehensive molecular view of cancer is important for ultimately guiding treatment, the National Cancer Institute (NCI)...
February 6, 2018
Best Performers Announced for the NCI-CPTAC DREAM Proteogenomics Computational Challenge

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce that teams led by Jaewoo Kang (Korea University), and Yuanfang Guan with Hongyang Li (University of Michigan) as the best performers of the NCI-CPTAC DREAM Proteogenomics Computational...
December 18, 2017
CPTAC Releases Cancer Proteome Confirmatory Colon Study Data

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) announces the release of the cancer proteome confirmatory colon study data. The goal of the study is to analyze the proteomes of approximately 100 confirmatory colon tumor patients, which includes tumor and...
December 5, 2017
CPTAC Evaluates Long-Term Reproducibility of Quantitative Proteomics Using Breast Cancer Xenografts

Liquid chromatography tandem-mass spectrometry (LC-MS/MS)- based methods such as isobaric tags for relative and absolute quantification (iTRAQ) and tandem mass tags (TMT) have been shown to provide overall better quantification accuracy and reproducibility over other LC-MS/MS techniques. However,...
November 27, 2017
CPTAC Develops LinkedOmics – Public Web Portal to Analyze Multi-Omics Data Within and Across Cancer Types

Multi-omics analysis has grown in popularity among biomedical researchers given the comprehensive characterization of thousands of molecular attributes in addition to clinical attributes. Several data portals have been devised to make these datasets directly available to the cancer research community...
November 15, 2017
P-MartCancer: A New Online Platform to Access CPTAC Datasets and Enable New Analyses

The November 1, 2017 issue of Cancer Research is dedicated to a collection of computational resource papers in genomics, proteomics, animal models, imaging, and clinical subjects for non-bioinformaticists looking to incorporate computing tools into their work. Scientists at Pacific Northwest National...
November 8, 2017
New KRAS Antibodies Available

Researchers estimate that approximately 30% of all human cancers are driven by RAS oncogenes. Mutated RAS genes are responsible for making RAS proteins that support cancer development. While anti-RAS therapies may have potential clinical benefit, researchers yet do not understand how the four RAS...

Pages

more

View all News and Announcements

NIH…Turning Discovery Into Health®